Press
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM (OTTAWA, March 22, 2023) Genomadix , based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” (CubeTM CYP2C19 Test), an automated sample-to-result PCR test. The CubeTM CYP2C19 Test is indicated …
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE
Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology. The Genomadix CubeTM uses polymerase chain reaction (PCR) technology in a small and portable …
Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic
Assets of Spartan Bioscience Inc. To Be Acquired By Casa-Dea Finance Limited
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Spartan Bioscience Inc. (Spartan) announces today that its primary assets will be acquired by a private company owned and led by Casa-Dea Finance Limited (Casa-Dea). In acquiring Spartan’s assets, Casa-Dea will strive to ensure that Spartan’s disruptive technology, and talented team of scientists, engineers and biotech professionals, will …
